How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15.

What other stocks do shareholders of Gemphire Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX) , Micron Technology (MU) , Pixelworks (PXLW) , SCYNEXIS (SCYX) , Alexion Pharmaceuticals (ALXN) , Clearside Biomedical (CLSD) , Intel (INTC) , Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT) .

When did Gemphire Therapeutics IPO?

Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

NASDAQ:GEMP

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free GEMP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $3.35
▼
$3.59
50-Day Range: $0.30
▼
$6.38
52-Week Range: $0.24
▼
$1.49

Volume: 22,788 shs
Average Volume: 127,174 shs
Market Capitalization: $51.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Gemphire Therapeutics alerts:

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Secure Your Spot Now

GEMP Stock News Headlines

May 11, 2023 | marketwatch.com

Hypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030

April 28, 2023 | marketwatch.com

Nonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 12, 2023 | marketwatch.com

2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updates

April 12, 2023 | marketwatch.com

2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updates

March 29, 2023 | marketwatch.com

Nonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027

March 26, 2023 | marketwatch.com

Global Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReports

March 24, 2023 | marketwatch.com

2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 2, 2023 | marketwatch.com

Hypertriglyceridemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029

March 1, 2023 | marketwatch.com

Hypertriglyceridemia Treatment Market 2023 Growth, Trends With the Rise in ICT Industry 2029

February 17, 2023 | marketwatch.com

Latest Hypertriglyceridemia Treatment Market Research Report (2023-2028)-Key Takeaways from Top Companies

February 15, 2023 | marketwatch.com

Worldwide Nonalcoholic Steatohepatitis (NASH) Market 2023 with Growth Analysis by Size and Share to 2027 | 99 Pages

January 24, 2023 | finance.yahoo.com

BiVictriX Therapeutics makes 'fundamental step forward'

April 6, 2022 | marketwatch.com

Hypertriglyceridemia Treatment Market Size 2022 Analysis Growth Report by Trends, Applications, Types, Competitive Strategies and Forecast to 2029

March 31, 2022 | marketwatch.com

Global Hypercholesterolemia Treatment Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028

October 13, 2021 | markets.businessinsider.com

NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification

See More Headlines

Receive GEMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GEMP
CUSIP: N/A
CIK: 1638287
Web: www.gemphire.com
Phone: 734-245-1700
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -419.70%
Return on Assets: -173.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.67
Quick Ratio: 0.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 6.37

Miscellaneous

Outstanding Shares: 14,872,000
Free Float: N/A
Market Cap: $51.16 million
Optionable: Not Optionable
Beta: 2.82

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Charles L. Bisgaier (Age 65)
Co-Founder, Chairman & Chief Scientific Officer
Dr. Steven R. Gullans (Age 66)
CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer
Mr. Seth Reno (Age 52)
Chief Commercial Officer
Mr. Jeffrey S. Mathiesen C.P.A. (Age 58)
CPA, Consultant
Ms. Amy Zaremba Rabourn
Director of Fin.

Key Competitors

View All Competitors

GEMP Stock Analysis - Frequently Asked Questions

How were Gemphire Therapeutics' earnings last quarter?: Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15.
What other stocks do shareholders of Gemphire Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Alexion Pharmaceuticals (ALXN), Clearside Biomedical (CLSD), Intel (INTC), Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT).
When did Gemphire Therapeutics IPO?: Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

This page (NASDAQ:GEMP) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

GEMP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GEMP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info